Epidemiological Burden of Non-Communicable Diseases and the Strategic Role of Biopharmaceutical Market Access: A Health Economics and Management Perspective

Abstract

Non-communicable diseases (NCDs) principally cardiovascular diseases, type 2 diabetes mellitus, chronic respiratory diseases, and cancers collectively account for approximately 74% of all global deaths annually, imposing an unprecedented epidemiological and economic burden on health systems across both developed and developing nations. Biopharmaceutical innovations, encompassing monoclonal antibodies, targeted small molecules, biologics, and advanced therapeutic modalities, have dramatically expanded the therapeutic options available for NCD management, yet access to these innovations remains profoundly inequitable across income groups and geographies. This study examines the intersection of NCD epidemiological burden and biopharmaceutical market access from a health economics and strategic management perspective, investigating how pricing strategies, reimbursement frameworks, supply chain architectures, and health technology assessment (HTA) systems influence the accessibility and affordability of biopharmaceutical interventions across high-income, middle-income, and low-income country contexts. A mixed-methods research design was employed, drawing on secondary epidemiological and health expenditure data from 40 countries supplemented by primary survey data from 50 health economics professionals, biopharmaceutical market access managers, and public health policymakers. Findings reveal that countries with institutionalized HTA frameworks and reference pricing mechanisms achieved biopharmaceutical affordability indices 36.7% higher than countries without such systems, while biosimilar market penetration a key driver of biopharmaceutical cost reduction varied dramatically from 68.4% in high-adoption markets to only 12.3% in low-adoption markets. Supply chain inefficiencies in NCD biopharmaceutical delivery were estimated to account for 18.4% of avoidable treatment costs in low- and middle-income country settings. The study proposes a Biopharmaceutical Access Optimization Framework integrating pricing governance, HTA infrastructure, biosimilar market development, and supply chain efficiency as four interdependent pillars of equitable NCD biopharmaceutical access.